MNKD Quote, Financials, Valuation and Earnings

Ionis Pharmaceuticals, Inc. has a net margin of 9.72% compared to MannKind Corp.'s net margin of -82.06%. MannKind Corp.'s return on equity of -- beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

MannKind Corp. has a consensus price target of $9.61, signalling upside risk potential of 71.93%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $90.67 which suggests that it could grow by 10.39%. Given that MannKind Corp. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe MannKind Corp. is more attractive than Ionis Pharmaceuticals, Inc..

MannKind Corp. has a beta of 0.815, which suggesting that the stock is 18.55% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.278, suggesting its less volatile than the S&P 500 by 72.158%.

MannKind Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MannKind Corp. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

MannKind Corp. quarterly revenues are $82.1M, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. MannKind Corp.'s net income of $8M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, MannKind Corp.'s price-to-earnings ratio is 59.34x while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MannKind Corp. is 5.50x versus 13.99x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Keros Therapeutics, Inc. has a net margin of 9.72% compared to MannKind Corp.'s net margin of -51.05%. MannKind Corp.'s return on equity of -- beat Keros Therapeutics, Inc.'s return on equity of 9.94%.

MannKind Corp. has a consensus price target of $9.61, signalling upside risk potential of 71.93%. On the other hand Keros Therapeutics, Inc. has an analysts' consensus of $23.38 which suggests that it could grow by 27.73%. Given that MannKind Corp. has higher upside potential than Keros Therapeutics, Inc., analysts believe MannKind Corp. is more attractive than Keros Therapeutics, Inc..

MannKind Corp. has a beta of 0.815, which suggesting that the stock is 18.55% less volatile than S&P 500. In comparison Keros Therapeutics, Inc. has a beta of 0.894, suggesting its less volatile than the S&P 500 by 10.599%.

MannKind Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Keros Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MannKind Corp. pays -- of its earnings as a dividend. Keros Therapeutics, Inc. pays out -- of its earnings as a dividend.

MannKind Corp. quarterly revenues are $82.1M, which are larger than Keros Therapeutics, Inc. quarterly revenues of $14.3M. MannKind Corp.'s net income of $8M is higher than Keros Therapeutics, Inc.'s net income of -$7.3M. Notably, MannKind Corp.'s price-to-earnings ratio is 59.34x while Keros Therapeutics, Inc.'s PE ratio is 11.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MannKind Corp. is 5.50x versus 3.02x for Keros Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 9.72% compared to MannKind Corp.'s net margin of -19.69%. MannKind Corp.'s return on equity of -- beat Moderna, Inc.'s return on equity of -30.18%.

MannKind Corp. has a consensus price target of $9.61, signalling upside risk potential of 71.93%. On the other hand Moderna, Inc. has an analysts' consensus of $37.70 which suggests that it could fall by -17.05%. Given that MannKind Corp. has higher upside potential than Moderna, Inc., analysts believe MannKind Corp. is more attractive than Moderna, Inc..

MannKind Corp. has a beta of 0.815, which suggesting that the stock is 18.55% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.170, suggesting its more volatile than the S&P 500 by 16.991%.

MannKind Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MannKind Corp. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

MannKind Corp. quarterly revenues are $82.1M, which are smaller than Moderna, Inc. quarterly revenues of $1B. MannKind Corp.'s net income of $8M is higher than Moderna, Inc.'s net income of -$200M. Notably, MannKind Corp.'s price-to-earnings ratio is 59.34x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MannKind Corp. is 5.50x versus 7.89x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of 9.72% compared to MannKind Corp.'s net margin of 34.76%. MannKind Corp.'s return on equity of -- beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

MannKind Corp. has a consensus price target of $9.61, signalling upside risk potential of 71.93%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $506.64 which suggests that it could grow by 6.85%. Given that MannKind Corp. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe MannKind Corp. is more attractive than Vertex Pharmaceuticals, Inc..

MannKind Corp. has a beta of 0.815, which suggesting that the stock is 18.55% less volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.310, suggesting its less volatile than the S&P 500 by 69.005%.

MannKind Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MannKind Corp. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

MannKind Corp. quarterly revenues are $82.1M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. MannKind Corp.'s net income of $8M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, MannKind Corp.'s price-to-earnings ratio is 59.34x while Vertex Pharmaceuticals, Inc.'s PE ratio is 33.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MannKind Corp. is 5.50x versus 10.47x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.